MARKET

KROS

KROS

Keros Therapeutics, Inc.
NASDAQ
21.23
-0.28
-1.30%
After Hours: 21.60 +0.37 +1.74% 17:36 12/15 EST
OPEN
21.09
PREV CLOSE
21.51
HIGH
21.29
LOW
20.73
VOLUME
572.23K
TURNOVER
--
52 WEEK HIGH
22.55
52 WEEK LOW
9.12
MARKET CAP
646.79M
P/E (TTM)
13.75
1D
5D
1M
3M
1Y
5Y
1D
Buy These 5 Best Value Stocks to Boost Your Portfolio in December
NASDAQ · 9h ago
Weekly Report: what happened at KROS last week (1208-1212)?
Weekly Report · 13h ago
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?
NASDAQ · 3d ago
Weekly Report: what happened at KROS last week (1201-1205)?
Weekly Report · 12/08 10:10
Largest borrow rate increases among liquid names
TipRanks · 12/04 13:45
Weekly Report: what happened at KROS last week (1124-1128)?
Weekly Report · 12/01 10:07
Keros Therapeutics Is Maintained at Neutral by B of A Securities
Dow Jones · 11/28 17:17
Keros Therapeutics Price Target Raised to $19.00/Share From $18.00 by B of A Securities
Dow Jones · 11/28 17:17
More
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Webull offers Keros Therapeutics Inc stock information, including NASDAQ: KROS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KROS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KROS stock methods without spending real money on the virtual paper trading platform.